Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2502213 | 1.00 | HTR2C (0.46) | HTR2CSMN1; SMN2NPC1RAB9APOLB | |
| SCHEMBL18340933 | 1.00 | HTR2C (0.46) | HTR2CSMN1; SMN2NPC1RAB9APOLB | |
| SCHEMBL1336851 | 0.86 | HTR2C (0.45) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL2493522 | 0.86 | HTR2C (0.45) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL17237781 | 0.86 | HTR2C (0.45) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL2356930 | 0.83 | HTR2C (0.41) | HTR2CSMN1; SMN2NPC1RAB9APOLB | |
| SCHEMBL2356933 | 0.83 | HTR2C (0.41) | HTR2CSMN1; SMN2NPC1RAB9APOLB | |
| SCHEMBL2317030 | 0.83 | HTR2C (0.41) | HTR2CSMN1; SMN2NPC1RAB9APOLB | |
| SCHEMBL10698128 | 0.81 | HTR2C (0.43) | HTR2CSMN1; SMN2NPC1RAB9APOLB | |
| SCHEMBL3005759 | 0.81 | CTSL (0.39) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3313828-B1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-10227331-B2 | Metallo-β-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180179190-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Marck Sharp & Dohme Corp. (US) | 2018-06-28 | — | — | US | disclosed |
| US-9585881-B2 | Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-03-07 | — | — | US | disclosed |
| US-9469609-B2 | Synthesis of pyrrolidine compounds | ZEALAND PHARMA A/S (DK) | 2016-10-18 | — | — | US | disclosed |
| US-20160287582-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-10-06 | — | — | US | disclosed |
| US-20150322007-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2015-11-12 | — | — | US | disclosed |
| WO-2011088045-A1 | AURORA KINASE COMPOUNDS AND METHODS OF THEIR USE | AMBIT BIOSCIENCES CORPORATION (US) | 2011-07-21 | — | — | WO | disclosed |
| US-7279584-B2 | Method for production of cis-4-fluoro-L-proline derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-09 | — | — | US | disclosed |
| US-20060281927-A1 | Process for production of cis-4-fluoro-l-proline derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-12-14 | — | — | US | disclosed |
| CN-1633446-A | Novel peptides as inhibitors of hepatitis C virus NS 3-serine protease | SCHERING CORP (US) | 2005-06-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160287582-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | F11, F9, F10 | HTR2C 4365/4885SMN1; SMN2 4340/4885NPC1 2246/4885 |
| US-20150322007-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | CPS1, DHPS, DDC | HTR2C 662/4885SMN1; SMN2 2087/4885NPC1 3626/4885 |
| US-10227331-B2 | Metallo-β-lactamase inhibitors | ALPI, GAA, ZFX | HTR2C 4810/4885SMN1; SMN2 1991/4885NPC1 1020/4885 |
| US-20180179190-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ALPI, GAA, ZFX | HTR2C 4801/4885SMN1; SMN2 2007/4885NPC1 1059/4885 |
| US-20060281927-A1 | Process for production of cis-4-fluoro-l-proline derivatives | PRAP1, P4HA1, SLC6A7 | HTR2C 2526/4885SMN1; SMN2 3700/4885NPC1 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.